Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014)

Bo Yu, Fei Luo, Bowen Sun, Wenxue Liu, Qiqi Shi, Shi Yuan Cheng, Ceshi Chen, Guoqiang Chen, Yanxin Li, Haizhong Feng

Research output: Contribution to journalComment/debatepeer-review

Abstract

Adv. Sci. 2021, 8, 2100014 DOI: 10.1002/advs.202100014 In the originally published article, the representative BLI images of treated mice in Figure 6D present the wrong samples (the third in the second row, and the third in the fourth row). The correct Figure 6D is shown below. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript. The authors regret the inconvenience this error may have caused. 6 Figure (Figure presented.) Targeting KAT6A sensitizes PD-L1 immunotherapy in TNBC by decreasing MDSCs recruitment. D) Representative BLI images of treated mice on Day 21.

Original languageEnglish (US)
Article number2105793
JournalAdvanced Science
Volume9
Issue number3
DOIs
StatePublished - Jan 25 2022

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Chemical Engineering(all)
  • Materials Science(all)
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Engineering(all)
  • Physics and Astronomy(all)

Fingerprint

Dive into the research topics of 'Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014)'. Together they form a unique fingerprint.

Cite this